Therapy-dependent modulation of Staphylococcus aureus colonization in atopic dermatitis: Insights from anti–IL-4/IL-13 and JAK inhibition - 19/05/26
Doi : 10.1016/j.jaad.2026.01.074
Federica Veronese, MD a, Chiara Maria Teresa Boggio, MSc b, Marta Armari, MSc b, Chiara Airoldi, PhD a, Elia Esposto, MD a, Elisa Zavattaro, MD a, c, Paola Savoia, MD a, c, ⁎ 
, Barbara Azzimonti, MSc b
, Barbara Azzimonti, MSc b a Dermatology Unit, AOU Maggiore della Carità, Novara, Italy
b Laboratory of Applied Microbiology, Department of Health Sciences (DiSS), Center for Translational Research on Allergic and Autoimmune Diseases (CAAD), School of Medicine, Università del Piemonte Orientale (UPO), Novara, Italy
c Dermatology Unit, Department of Health Sciences (DiSS), School of Medicine, Università del Piemonte Orientale (UPO), Novara, Italy
∗ Correspondence to: Paola Savoia, MD, Department of Health Sciences, Università del Piemonte Orientale (UPO), Via Solaroli 17, Novara, 28100, Italy Department of Health Sciences Università del Piemonte Orientale (UPO) Via Solaroli 17 Novara 28100 Italy
Key words : atopic dermatitis, dupilumab, IL-4/IL-13 blockade, JAK inhibitor, skin microbiome, Staphylococcus aureus, upadacitinib
| Dr Veronese and Dr Boggio share first name co-authorship. |
|
| Dr Armari and Dr Airoldi share second name co-authorship. |
|
| Funding sources: B.A., C.M.T.B., and P.S. have been financed by “Progetti di ricerca di rilevante interesse nazionale—Bando 2022 PNRR, Prot. P2022N2XWH.” M.A. holds a PhD career grant supported by Next Generation EU—MUR (Italy) for the PhD program in “Food, Health, and Longevity Studies, 39th cycle.” |
|
| Patient consent: This study was conducted in accordance with ethical standards and guidelines for research involving human participants. Written informed consent was obtained from all participants prior to inclusion in the study. Participants were informed of the study purpose, procedures, risks, benefits, and their right to withdraw at any time without consequence. All personal health information has been handled confidentially and anonymized to protect participant privacy. |
|
| IRB approval status: The study was approved by the local ethics committee (CE 411/2023). |
© 2026
The Author(s). Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 94 - N° 6
P. 1782-1784 - juin 2026 Retour au numéro
Article précédent
- Safety and clinical response of tumor necrosis factor-α inhibitor adalimumab in the treatment of severe acne: A real-world study
- Zhuokun Liu, Xin Liu, Yufei Wu, Jialin Lian, Danyang Yang, Jiayi Han, Ruilian Li, Chenyue Liu, Xiaoli Li
- Identifying cutaneous dermatomyositis disease area and severity index thresholds of disease severity in alignment with patient perspectives on quality of life: A retrospective analysis
- Sarah Jun, Hammad Ali, Touraj Khosravi-Hafshejani, Sarini Saksena, Elena Wei, Ahmed Eldaboush, Rafael Ozan Homer, Lais Lopes Almeida Gomes, Rui Feng, Victoria P. Werth
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?